Conmed (CNMD) Tops Q4 EPS by 8c, Offers Guidance

Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.84, $0.08 better than the analyst estimate of $0.76. Revenue for the quarter came in at $252.8 million versus the consensus estimate of $262.94 million.

GUIDANCE:

Conmed sees FY2021 EPS of $2.85-$3.05, versus the consensus of $3.02. Conmed sees FY2021 revenue of $975-1020 million, versus the consensus of $1020 million.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Evogene (EVGN) Tops Q2 EPS by 15c
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41